RecruitingPhase 3NCT06914609
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
Studying Angelman syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Intervention
- ION582(drug)
- Enrollment
- 158 enrolled
- Eligibility
- 2-50 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Rady Children's Hospital, San Diego, California, United States
- Colorado Children's Hospital Research Institute, Aurora, Colorado, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Children's Mercy, Kansas City, Missouri, United States
- Ichan School of Medicine at Mount Sinai, New York, New York, United States
- University of North Carolina at Chapel Hill School of Medicine, Carrboro, North Carolina, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Vanderbilt Clinical Research Center, Nashville, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
- Queensland Children's Hospital, South Brisbane, Queensland, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06914609 on ClinicalTrials.govOther trials for Angelman syndrome
Additional recruiting or active studies for the same condition.